1. Home
  2. AL vs AKRO Comparison

AL vs AKRO Comparison

Compare AL & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AL
  • AKRO
  • Stock Information
  • Founded
  • AL 2010
  • AKRO 2017
  • Country
  • AL United States
  • AKRO United States
  • Employees
  • AL N/A
  • AKRO N/A
  • Industry
  • AL Diversified Commercial Services
  • AKRO Biotechnology: Pharmaceutical Preparations
  • Sector
  • AL Consumer Discretionary
  • AKRO Health Care
  • Exchange
  • AL Nasdaq
  • AKRO Nasdaq
  • Market Cap
  • AL 4.7B
  • AKRO 3.9B
  • IPO Year
  • AL 2011
  • AKRO 2019
  • Fundamental
  • Price
  • AL $56.78
  • AKRO $50.73
  • Analyst Decision
  • AL Buy
  • AKRO Strong Buy
  • Analyst Count
  • AL 5
  • AKRO 8
  • Target Price
  • AL $58.80
  • AKRO $82.50
  • AVG Volume (30 Days)
  • AL 1.2M
  • AKRO 1.9M
  • Earning Date
  • AL 05-05-2025
  • AKRO 05-12-2025
  • Dividend Yield
  • AL 1.53%
  • AKRO N/A
  • EPS Growth
  • AL 15.59
  • AKRO N/A
  • EPS
  • AL 5.72
  • AKRO N/A
  • Revenue
  • AL $2,808,629,000.00
  • AKRO N/A
  • Revenue This Year
  • AL $9.67
  • AKRO N/A
  • Revenue Next Year
  • AL $7.47
  • AKRO N/A
  • P/E Ratio
  • AL $10.07
  • AKRO N/A
  • Revenue Growth
  • AL 3.56
  • AKRO N/A
  • 52 Week Low
  • AL $38.25
  • AKRO $17.86
  • 52 Week High
  • AL $59.27
  • AKRO $58.40
  • Technical
  • Relative Strength Index (RSI)
  • AL 63.20
  • AKRO 64.52
  • Support Level
  • AL $55.59
  • AKRO $44.94
  • Resistance Level
  • AL $58.49
  • AKRO $51.66
  • Average True Range (ATR)
  • AL 1.10
  • AKRO 3.29
  • MACD
  • AL -0.28
  • AKRO 0.73
  • Stochastic Oscillator
  • AL 36.15
  • AKRO 91.10

About AL Air Lease Corporation

Air Lease Corp is an aircraft leasing company based in the United States. It is engaged in purchasing commercial jet aircrafts directly from aircraft manufacturers and leasing those aircraft to airlines throughout the world to generate attractive returns on equity. The company also sells aircraft from its fleet to third parties, including other leasing companies, financial services companies, airlines, and other investors, and offers fleet management services to investors and owners of aircraft portfolios for a management fee. Geographically, it derives a majority of its revenue from the Asia-Pacific region and the rest from Europe, Middle East and Africa, Central America, South America, Mexico, the United States, and Canada.

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

Share on Social Networks: